- Product Partners
- Supplements Facts
- Scientific References
- Client Reviews
Support Your Vision With the Latest in Eye Health…
TrueVision™ is formulated to help protect and bolster the vision in people of all ages.
It features the Lutemax 20/20™, which uniquely provides all three carotenoids your eyes need to protect the macula - lutein, RR-zeaxanthin and RS-zeaxanthin. These nutrients come from a natural source, the marigold flower. Even those who eat a healthy, balanced diet struggle to get adequate amount of these three nutrients - making a supplement valuable to vision health.
Together, lutein and the two zeaxanthin isomers produce a yellow pigment in the macula which acts as a protective shield against harmful rays. This pigment protects the macula and retina from harmful “blue light” and oxidation damage. Maintaining optimal levels of macular pigment has been shown to help protect against age-related vision concerns.
Research has shown that supplementing with lutein and zeaxanthin may help improve central eyesight, glare recovery and contrast sensitivity (e.g. see better in dim light).
The emerging vision health superstar is the most prized spice in the world - saffron.
Recent research has shown that saffron helps protect photoreceptor cells from oxidative stress - making them more resilient and less likely to die. Photoreceptor cells are critical to vision health because they convert light your eyes see to signals that your brain uses to determine what you’re seeing. In addition, saffron helps increase blood and oxygen flow in the eye - and helps maintain healthy intraocular eye pressure levels.
Saffron has been shown to help significantly improve reading ability, being able to see in low light and in contrast and color perception. TrueVision™ provides 20mg of saffron per serving from the patented Satiereal® extract.
Lutemax 20/20™: A Natural Source of Lutein, RR-Zeaxanthin
Serving Size: 1 Capsule / Servings per Container: 30
|Active Ingredients||Amount Per Serving|
|Lutein (Lutemax 2020™ from marigold flower)||10 mg*|
|Zeaxanthin isomers (RR-zeaxanthin and RS (meso)-zeaxanthin ) (Lutemax 2020™ from marigold flower)||2 mg*|
|Satiereal® Saffron stigma extract (Crocus sativus L.)||120 mg*|
* Daily value not established.
Other ingredients: rice flour, hypromellose, vegetable magnesium stearate and silica.
Lutemax 2020™ is a trademark of OmniActive Health Technologies Ltd. Satiereal® is a trademark of INOREAL. International patents pending.
Suggested Use: Take one (1) capsule daily with meals or as directed by your health care practitioner.
TrueVision™ is formulated to help you support and maintain healthy vision.+
Keep out of the reach of children
Store in a cool dry place
Do not use if seal is broken or missing
- Gluten Free
- BPA Free
- Assembled in the USA
†These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Manufactured for and Distributed by: NatureCity®
Boca Raton, FL 33487 • www.naturecity.com
To re-order call toll free 1-800-593-2563
Luetin and Zeaxanthin
Stringham JM, Stringham NT. “Serum and retinal responses to three different doses of macular carotenoids over 12 weeks of supplementation.” Experimental Eye Research. 2016 Jul 15;151:1-8.
Berrow EJ, Bartlett HE, Eperjesi F. “The effect of nutritional supplementation on the multifocal electroretinogram in healthy eyes.” Doc Ophthalmol. 2016 Apr;132(2):123-35.
Murillo AG, Fernandez ML. “Potential of Dietary Non-Provitamin A Carotenoids in the Prevention and Treatment of Diabetic Microvascular Complications.” Advances in Nutrition 2016 Jan 15;7(1):14-24.
Bernstein PS, Li B, Vachali PP, Gorusupudi A, Shyam R, Henriksen BS, Nolan JM. “Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease.” Progress in Retinal and Eye Research. 2016 Jan;50:34-66.
Wolf-Schnurrbusch UE, Zinkernagel MS, Munk MR, Ebneter A, Wolf S. “Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids.” Investigative Ophthalmology & Visual Science. 2015 Dec 1;56(13):8069-74.
Wu J1, Cho E2, Willett WC3, Sastry SM4, Schaumberg DA5. “Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up.” JAMA Ophthalmology. 2015 Dec 1;133(12):1415-24.
Mamatha BS, Nidhi B, Padmaprabhu CA, Pallavi P, Vallikannan B. “Risk Factors for Nuclear and Cortical Cataracts: A Hospital Based Study.” Journal of Ophthalmic and Vision Research. 2015 Jul-Sep;10(3):243-9.
Kelly D, Coen RF, Akuffo KO, Beatty S, Dennison J, Moran R, Stack J, Howard AN, Mulcahy R, Nolan JM. “Cognitive Function and Its Relationship with Macular Pigment Optical Density and Serum Concentrations of its Constituent Carotenoids.” Journal of Alzheimers Disease. 2015;48(1):261-77.
Huang YM, Dou HL, Huang FF, Xu XR, Zou ZY, Lin XM. “Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration.” Biomed Research International. 2015;2015:564738.
Akuffo KO, Nolan JM, Howard AN, Moran R, Stack J, Klein R, Klein BE, Meuer SM, Sabour-Pickett S, Thurnham DI, Beatty S. “Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration.” Eye. 2015 Jul;29(7):902-12.
Bovier ER, Hammond BR. “A randomized placebo-controlled study on the effects of lutein and zeaxanthin on visual processing speed in young healthy subjects.” Archives of Biochemistry and Biophysics. 2015 Apr 15;572:54-7.
Nolan JM, Loskutova E, Howard A, Mulcahy R, Moran R, Stack J, Bolger M, Coen RF, Dennison J, Akuffo KO, Owens N, Power R, Thurnham D, Beatty S. “The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial.” Journal of Alzheimers Disease. 2015;44(4):1157-69.
Huang YM, Dou HL, Huang FF, Xu XR, Zou ZY, Lu XR, Lin XM. “Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial.” British Journal of Ophthalmology. 2015 Mar;99(3):371-5.
Liu R, Wang T, Zhang B, Qin L, Wu C, Li Q, Ma L. “Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration.” Investigative Ophthalmology & Visual Science. 2014 Dec 16;56(1):252-8.
Hammond BR, Fletcher LM, Roos F, Wittwer J, Schalch W. “A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast.” Investigative Ophthalmology & Visual Science. 2014 Dec 2;55(12):8583-9.
Johnson EJ. “Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan.” Nutrition Reviews. 2014 Sep;72(9):605-12.
Sabour-Pickett S, Beatty S, Connolly E, Loughman J, Stack J, Howard A, Klein R, Klein BE, Meuer SM, Myers CE, Akuffo KO, Nolan JM. “Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration.” Retina. 2014 Sep;34(9):1757-66.
Bovier ER, Renzi LM, Hammond BR. “A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency." PLOS One. 2014 Sep 24;9(9):e108178.
Sawa M, Gomi F, Hara C, Nishida K. “Effects of a lutein supplement on the plasma lutein concentration and macular pigment in patients with central serous chorioretinopathy.” Investigative Ophthalmology & Visual Science. 2014 Jul 29;55(8):5238-44.
Bibiloni Mdel M, Zapata ME, Aragón JA, Pons A, Olea JL, Tur JA. “Estimation of antioxidants dietary intake in wet age-related macular degeneration patients.” Nutrición Hospitalaria. 2014 Apr 1;29(4):880-8.
Thomson RL, Coates AM, Howe PR, Bryan J, Matsumoto M, Buckley JD. “Increases in plasma lutein through supplementation are correlated with increases in physical activity and reductions in sedentary time in older adults.” Nutrients. 2014 Mar 3;6(3):974-84.
Grover AK, Samson SE. “Antioxidants and vision health: facts and fiction.” Molecular and Cellular Biochemistry. 2014 Mar;388(1-2):173-83.
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD. “Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.” JAMA Ophthalmology. 2014 Feb;132(2):142-9.
Liu XH, Yu RB, Liu R, Hao ZX, Han CC, Zhu ZH, Ma L. “Association between lutein and zeaxanthin status and the risk of cataract: a meta-analysis.” Nutrients. 2014 Jan 22;6(1):452-65.
Meyers KJ, Mares JA, Igo RP Jr, Truitt B, Liu Z, Millen AE, Klein M, Johnson EJ, Engelman CD, Karki CK, Blodi B, Gehrs K, Tinker L, Wallace R, Robinson J, LeBlanc ES, Sarto G, Bernstein PS, SanGiovanni JP, Iyengar SK. “Genetic evidence for role of carotenoids in age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS).” Investigative Ophthalmology & Visual Science. 2014 Jan 29;55(1):587-99.
Ma L, Hao ZX, Liu RR, Yu RB, Shi Q, Pan JP. “A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract.” Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):63-70.
Dawczynski J1, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J. “Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.” Graefe’s Archive for Clinical and Experimental Ophthalmology. 2013 Dec;251(12):2711-23.
Meagher KA, Thurnham DI, Beatty S, Howard AN, Connolly E, Cummins W, Nolan JM. “Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration.” British Journal of Nutrition. 2013 Jul 28;110(2):289-300.
Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry NR, Berendschot TT. “Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study.” Investigative Ophthalmology & Visual Science. 2013 Mar 11;54(3):1781-8.
Hammond BR Jr, Fletcher LM, Elliott JG. “Glare disability, photostress recovery, and chromatic contrast: relation to macular pigment and serum lutein and zeaxanthin.” Investigative Ophthalmology & Visual Science. 2013 Jan 17;54(1):476-81.
Ma L, Yan SF, Huang YM, Lu XR, Qian F, Pang HL, Xu XR, Zou ZY, Dong PC, Xiao X, Wang X, Sun TT, Dou HL, Lin XM. “Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration.” Ophthalmology. 2012 Nov;119(11):2290-7.
Loughman J1, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S. “The impact of macular pigment augmentation on visual performance using different carotenoid formulations.” Investigative Ophthalmology & Visual Science. 2012 Nov 29;53(12):7871-80.
Ma L, Dou HL, Huang YM, Lu XR, Xu XR, Qian F, Zou ZY, Pang HL, Dong PC, Xiao X, Wang X, Sun TT, Lin XM. “Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial.” American Journal of Ophthalmology. 2012 Oct;154(4):625-634.e1.
Tanito M, Obana A, Gohto Y, Okazaki S, Gellermann W, Ohira A. “Macular pigment density changes in Japanese individuals supplemented with lutein or zeaxanthin: quantification via resonance Raman spectrophotometry and autofluorescence imaging.” Japanese Journal of Ophthalmology. 2012 Sep;56(5):488-96.
Richer SP, Stiles W, Graham-Hoffman K, Levin M, Ruskin D, Wrobel J, Park DW, Thomas C. “Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973.” Optometry. 2011 Nov;82(11):667-680.e6.
Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhöfer G, Schmidt-Erfurth U, Schmetterer L. “Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration.” Investigative Ophthalmology & Visual Science. 2011 Oct 17;52(11):8174-8.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC, Johnson EJ, Anderson EJ, Johnson CA, Gaudio AR, Willett WC, Schaefer EJ. “Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A.” Archives of Ophthalmology. 2010 Apr;128(4):403-11.
Ma L, Lin XM. “Effects of lutein and zeaxanthin on aspects of eye health.” Journal of the Science of Food and Agriculture. 2010 Jan 15;90(1):2-12.
Ma L1, Lin XM, Zou ZY, Xu XR, Li Y, Xu R. “A 12-week lutein supplementation improves visual function in Chinese people with long-term computer display light exposure.” British Journal of Nutrition. 2009 Jul;102(2):186-90.
Moeller S, Voland R, Tinker L, Blodi B, Klein M, Gehrs K, Johnson E, Snodderly M, Wallace R, Chappell R Parekh N, Ritenbaugh C, Mares J. “Associations Between Age-Related Nuclear Cataract and Lutein and Zeaxanthin in the Diet and Serum in the Carotenoids in the Age-Related Eye Disease Study (CAREDS), an Ancillary Study of the Women's Health Initiative.” JAMA Ophthalmology. 2008; Mar;126(3):354-364.
Krinsky N, Landrum J, Bone R. Biologic Mechanisms of the Protective Role of Lutein and Zeaxanthin in the Eye. Annual Review of Nutrition. Vol. 23: 171-201 (Volume publication date July 2003).
Gale C, Hall N, Phillips D, Martyn C. “Lutein and Zeaxanthin Status and Risk of Age-Related Macular Degeneration.” Investigative Ophthalmology & Visual Science. June 2003, Vol.44, 2461-2465.
Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD. “Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey.” American Journal of Epidemiology. 2001 Mar 1;153(5):424-32.
Jabbarpoor Bonyadi MH, Yazdani S, Saadat S. “The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study.” BMC Complementary and Alternative Medicine. 2014 Oct 15;14:399.
Bisti S, Maccarone R, Falsini B. “Saffron and retina: neuroprotection and pharmacokinetics.” Visual Neuroscience. 2014 Sep;31(4-5):355-61.
Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, Farsad F, Kamalipour M, Akhondzadeh S. “Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial.” Human Psychopharmacology. 2014 Jul;29(4):351-9.
Shahmansouri N, Farokhnia M, Abbasi SH, Kassaian SE, Noorbala Tafti AA, Gougol A, Yekehtaz H, Forghani S, Mahmoodian M, Saroukhani S, Arjmandi-Beglar A, Akhondzadeh S. “A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients.” Journal of Affective Disorders. 2014 Feb;155:216-22.
Kashani L1, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi AA, Jamshidi A, Ashrafi M, Mansouri P, Ghaeli P, Akhondzadeh S. “Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study.” Human Psychopharmacology. 2013 Jan;28(1):54-60.
Marangoni D, Falsini B, Piccardi M, Ambrosio L, Minnella AM, Savastano MC, Bisti S, Maccarone R, Fadda A, Mello E, Concolino P, Capoluongo E. “Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report.” Journal of Translational Medicine. 2013 Sep 25;11:228.
Piccardi, M, Marangoni D, Minnella A, Savastano M, Valentini P, Ambrosio L, Capoluongo E, Maccarone R, Bisti S, Falsini B. “A Longitudinal Follow-Up Study of Saffron Supplementation in Early Age-Related Macular Degeneration: Sustained Benefits to Central Retinal Function.” Evidence-Based Complementary and Alternative Medicine. Volume 2012 (2012;May), Article ID 429124, 9 pages.
Falsini B, Piccardi M, Minnella A, Savastano C, Capoluongo E, Fadda A, Balestrazzi E, Maccarone R, Bisti S. “Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration.” Investigative Ophthalmology & Visual Science. 2010 Dec;51(12):6118-24.
Gout B, Bourges C, Paineau-Dubreuil S. “Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women.” Nutrition Research. 2010 May;30(5):305-13.
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. “Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial.” Journal of Clinical Pharmacy and Therapeutics. 2010 Oct;35(5):581-8.
Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. “A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease.” Psychopharmacology. 2010 Jan;207(4):637-43.
Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. “Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial.” Progress in Neuropsychopharmacology & Biological Psychiatry. 2007 Mar 30;31(2):439-42.
Moshiri E1, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. “Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial.” Phytomedicine. 2006 Nov;13(9-10):607-11.
Akhondzadeh S1, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. “Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial.” Phytotherapy Research. 2005 Feb;19(2):148-51.
Akhondzadeh S1, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. “Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816].” BMC Complement and Alternative Medicine. 2004 Sep 2;4:12.
*The views and opinions expressed by contributors and or product reviews are their own and not
necessarily those of NatureCity. These reviews should not be taken as recommendations but rather
client opinions of the products that they have used.